3-[2-(3-Oxopropoxy)ethoxy]propanal | 151709-76-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-[2-(3-Oxopropoxy)ethoxy]propanal
• CAS: 151709-76-1
• 化学式: C₈H₁₄O₄
• 分子量: 174.19
• InChiKey: AISUWRBCTRKCEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  12
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS
  申请人：Fetzer Oliver S.

  公开号：US20120213854A1

  公开（公告）日：2012-08-23

  Described herein are methods for treating a subject with combinations of polymer-agent particles and cyclodextrin polymer agent conjugates. The methods herein may be used to treat subjects identified with cancer, cardiovascular disorders, autoimmune disorders, or inflammatory disorders. Also described herein are compositions, dosage forms, and kits comprising polymer-agent particles and cyclodextrin polymer agent conjugates.

  本文介绍了使用聚合物-药剂颗粒和环糊精聚合物药剂共轭物的组合治疗方法来治疗患有癌症、心血管疾病、自身免疫性疾病或炎症性疾病的受试者。本文还描述了包含聚合物-药剂颗粒和环糊精聚合物药剂共轭物的组合物、剂型和套装。
• CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY
  申请人：Cerulean Pharma Inc.

  公开号：US20140378414A1

  公开（公告）日：2014-12-25

  Methods and compositions relating to CDP-proteasome inhibitor conjugates are described herein.

  本文描述了与CDP-蛋白酶体抑制剂结合物相关的方法和组合物。
• CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
  申请人：Ryan John

  公开号：US20140288024A1

  公开（公告）日：2014-09-25

  Methods and compositions relating to CDP-epothilone conjugates are described herein.

  本文描述了与CDP-epothilone结合物相关的方法和组合物。
• TARGETED ENZYME COMPOUNDS AND USES THEREOF
  申请人：ANGIOCHEM INC.

  公开号：US20160367691A1

  公开（公告）日：2016-12-22

  The present invention is related to the one-step synthesis of enzyme conjugates and methods for treating or preventing MPS-II by administering such conjugates. In certain embodiments, these compounds can cross the blood-brain barrier or accumulate in the lysosome more effectively than the enzyme alone.
• TREATMENT OF CANCER
  申请人：Ellipses Pharma Limited

  公开号：US20200375978A1

  公开（公告）日：2020-12-03

  Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.